Schrödinger, Inc. (SDGR)
NasdaqGS · USD · Healthcare · Health Information Services
$24.50 (+2.94%) as of
Key statistics
- Market cap
- 1.83B
- Forward P/E
- -18.15
- EPS (TTM)
- -0.76
- Dividend yield
- 0.00%
- 52-week range
- 10.94 – 33.78
- Beta
- 1.62
- Revenue (TTM)
- 259.04M
- Profit margin
- -20.98%
- Analyst target
- $25.86
- Volume
- 1.26M
About Schrödinger, Inc.
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally. The company operates in two segments, Software and Drug Discovery. The Software segment sells its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. It has a research collaboration and license agreement with Novartis Pharma AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Health Information Services
- Headquarters
- New York, NY, United States
- Employees
- 850
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.